Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
23 sept. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
20 sept. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress
31 août 2022 08h48 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
10 août 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
09 août 2022 08h00 HE
|
Alimera Sciences, Inc.
Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global...
Alimera Sciences Announces Second Quarter 2022 Financial Results
27 juil. 2022 07h30 HE
|
Alimera Sciences, Inc.
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021U.S. End User Demand up 45% vs. Second Quarter of 2021International Segment End User Demand Up 21% vs. Second Quarter...
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
26 juil. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
22 juil. 2022 10h34 HE
|
Alimera Sciences, Inc.
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
22 juil. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress
13 juil. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, July 13, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...